1260H listing moves WuXi AppTec toward BIOSECURE procurement ban

The June 8 update to the Section 1260H list is the moment WuXi AppTec stops being a BIOSECURE Act hypothetical and becomes a contracting problem. The update added the China-based contract research, development and manufacturing organization to the Chinese military company list. Section 851 of the Fiscal Year 2026 National Defense Authorization Act, the BIOSECURE Act, bars executive agencies from procuring biotechnology equipment or services from biotechnology companies of concern and restricts federal loan and grant funding for those purchases. A 1260H listing gives the Office of Management and Budget (OMB) a direct route to put WuXi AppTec on that list.

This is more than list maintenance. The Government Accountability Office reported in February that DoD has invested about $965 million since 2020 in domestic biomanufacturing and identified overreliance on foreign suppliers as a defense industrial-base risk (https://www.gao.gov/products/gao-26-107797). WuXi AppTec's listing lands inside that larger campaign: the government is building domestic biotechnology capacity while narrowing the federal market for services tied to companies of concern.

Why WuXi moved out of the gray zone

Earlier BIOSECURE drafts expressly named WuXi AppTec. The enacted statute did not, leaving contractors with a supplier Congress had already identified but OMB had not yet put on the operative list. The 1260H designation closes most of that space. OMB still has to publish the formal BCOC list, due by Dec. 18, 2026, and determine that WuXi AppTec is involved to any extent in biotechnology equipment or services. Given the company's business, that determination looks like a low hurdle.

WuXi AppTec has challenged its 1260H inclusion in the U.S. District Court for the District of Columbia, and the case was pending when Covington published its analysis. Counsel will track that litigation. Procurement teams still need to assume that an active federal biotech supply chain with WuXi AppTec in it is now exposed.

The procurement clock has two hands

BIOSECURE creates the governmentwide procurement problem. Primes and subcontractors using WuXi AppTec for biotech research and development, manufacturing or testing face a future bar on federal awards and potential termination risk if they cannot identify and sever the relationship when OMB makes the designation operative. OMB has not set the divestment deadline or issued implementing guidance, which is due six months after the BCOC list. That timing is the ugly part: supply-chain mapping takes longer than list publication.

Separately, Section 805 of the Fiscal Year 2024 National Defense Authorization Act applies only to defense procurements but starts sooner. From June 30, 2026, the department is prohibited from procuring goods, services or technology from 1260H entities and entities under their control. From June 30, 2027, the bar extends to goods or services that include goods or services produced or developed by them. The Defense Federal Acquisition Regulation Supplement amendment has not begun, and the unresolved word is "include," especially because the statute exempts components.

What practitioners do before OMB finishes

Start with the inventory. Contractors should identify WuXi AppTec use across prime contracts, subcontracts, federal grants and loans; separate direct WuXi AppTec services from other WuXi entities; and preserve records showing the search, any divestment plan and communications with contracting officers. C3PAOs pulled into affected customer work should focus on the evidence trail: supplier lists, flowdowns and dates. Congress's direction is plain; the unresolved piece is proving where WuXi AppTec is already embedded before OMB fills in the blanks.